Cargando…

A deep eutectic-based, self-emulsifying subcutaneous depot system for apomorphine therapy in Parkinson’s disease

Apomorphine, a dopamine agonist, is a highly effective therapeutic to prevent intermittent off episodes in advanced Parkinson’s disease. However, its short systemic half-life necessitates three injections per day. Such a frequent dosing regimen imposes a significant compliance challenge, especially...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Jayoung, Gao, Yongsheng, Zhao, Zongmin, Rodrigues, Danika, Tanner, Eden E. L., Ibsen, Kelly, Sasmal, Pradip K., Jaladi, Rajasekhar, Alikunju, Shanavas, Mitragotri, Samir
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	National Academy of Sciences 2022
Materias:	Physical Sciences
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8892321/ https://www.ncbi.nlm.nih.gov/pubmed/35197281 http://dx.doi.org/10.1073/pnas.2110450119

Ejemplares similares

Deep Eutectic Solvents for Subcutaneous Delivery of Protein Therapeutics
por: Curreri, Alexander M., et al.
Publicado: (2023)

Apomorphine formulation may influence subcutaneous complications from continuous subcutaneous apomorphine infusion in Parkinson’s disease
por: Hagell, Peter, et al.
Publicado: (2020)

Erythrocyte leveraged chemotherapy (ELeCt): Nanoparticle assembly on erythrocyte surface to combat lung metastasis
por: Zhao, Zongmin, et al.
Publicado: (2019)

Population pharmacokinetic analysis of apomorphine sublingual film or subcutaneous apomorphine in healthy subjects and patients with Parkinson’s disease
por: Agbo, Felix, et al.
Publicado: (2021)

Ionic liquids for addressing unmet needs in healthcare
por: Agatemor, Christian, et al.
Publicado: (2018)

Apomorphine Subcutaneous Injection for the Management of Morning Akinesia in Parkinson's Disease
por: Isaacson, Stuart, et al.
Publicado: (2016)

Apomorphine
Publicado: (1900)

Apomorphine
Publicado: (1888)

Continuous Subcutaneous Apomorphine Infusion in Advanced Parkinson’s Disease: A Systematic Review
por: Gaire, Suman, et al.
Publicado: (2021)

Red Blood Cell Anchoring Enables Targeted Transduction and Re‐Administration of AAV‐Mediated Gene Therapy
por: Zhao, Zongmin, et al.
Publicado: (2022)

Apomorphine effects on the hippocampus
por: Arroyo-García, Luis Enrique, et al.
Publicado: (2018)

On the Anæsthetic Action of Apomorphine
Publicado: (1885)

Injectable hyaluronic acid hydrogels encapsulating drug nanocrystals for long‐term treatment of inflammatory arthritis
por: Gao, Yongsheng, et al.
Publicado: (2021)

Feasibility and benefits of home initiation of subcutaneous apomorphine infusion for patients with Parkinson’s disease: the APOKADO study
por: Zagnoli, Fabien, et al.
Publicado: (2023)

Pharmacokinetics and Comparative Bioavailability of Apomorphine Sublingual Film and Subcutaneous Apomorphine Formulations in Patients with Parkinson’s Disease and “OFF” Episodes: Results of a Randomized, Three-Way Crossover, Open-Label Study
por: Agbo, Felix, et al.
Publicado: (2021)

A polymer‐based systemic hemostat for managing uncontrolled bleeding
por: Gao, Yongsheng, et al.
Publicado: (2023)

Clinical translation of choline and geranic acid deep eutectic solvent
por: Ko, Justin, et al.
Publicado: (2020)

Gemcitabine and doxorubicin in immunostimulatory monophosphoryl lipid A liposomes for treating breast cancer
por: Wu, Debra, et al.
Publicado: (2020)

Some Observations on the Use of Apomorphine
por: Horsley, J. S.
Publicado: (1912)

Is Apomorphine a Safe Emetic?
por: Brown, John
Publicado: (1889)

Continuous subcutaneous apomorphine infusion allowing awake deep brain stimulation in a Parkinson’s disease patient
por: Spagnolo, Francesca, et al.
Publicado: (2021)

Neuropathy and neural plasticity in the subcutaneous white adipose depot
por: Blaszkiewicz, Magdalena, et al.
Publicado: (2019)

Digital therapeutics in the clinic
por: Phan, Philana, et al.
Publicado: (2023)

Ventricular Bigeminy after Subcutaneous Administration of Apomorphine in a Patient with Refractory Parkinson’s Disease: A Case Report
por: Kaminioti, Anastasia N., et al.
Publicado: (2013)

Continuous subcutaneous apomorphine infusion in the early phase of advanced Parkinson’s disease: A prospective study of 22 patients
por: Fernández-Pajarín, Gustavo, et al.
Publicado: (2021)

Recent Advances in Ionic Liquids in Biomedicine
por: Curreri, Alexander M., et al.
Publicado: (2021)

Apomorphine Hydrochloride in the Treatment of Persistent Hiccough
por: Panda, R. C.
Publicado: (1928)

The Pharmacological Properties and Therapeutic Use of Apomorphine
por: Ribarič, Samo
Publicado: (2012)

Apomorphine in Parkinson's Disease—The Questions Raised
por: Dhamija, Rajinder K., et al.
Publicado: (2020)

Looking Beyond the Fog—Apomorphine Demystified
por: LK, Prashanth, et al.
Publicado: (2020)

Necrotic Ulcers Secondary to Apomorphine Infusion
por: Llamas-Osorio, Yudy, et al.
Publicado: (2021)

Abdominal Subcutaneous Adipose Tissue: A Protective Fat Depot?
por: Porter, Stacy A., et al.
Publicado: (2009)

Ovulation suppression following subcutaneous administration of depot medroxyprogesterone acetate
por: Taylor, Douglas J., et al.
Publicado: (2022)

Inherited basis of visceral, abdominal subcutaneous and gluteofemoral fat depots
por: Agrawal, Saaket, et al.
Publicado: (2022)

Viral vector‐based gene therapies in the clinic
por: Zhao, Zongmin, et al.
Publicado: (2021)

Continuous Subcutaneous Apomorphine Infusion before Subthalamic Deep Brain Stimulation: A Prospective, Comparative Study in 20 Patients
por: Fernández‐Pajarín, Gustavo, et al.
Publicado: (2021)

A Case of Hiccough Cured with Apomorphine Hydrochloride
por: Dutt, K. N.
Publicado: (1933)

Apomorphine Targets the Pleiotropic Bacterial Regulator Hfq
por: Turbant, Florian, et al.
Publicado: (2021)

A Long‐Lasting Skin Protectant Based on CG‐101, a Deep Eutectic Solvent Comprising Choline and Geranic Acid
por: Shevachman, Marina, et al.
Publicado: (2022)

RNA therapeutics in the clinic
por: Curreri, Alexander, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_p8l8hvp7q3chdfi2jk52814er5